Results 91 to 100 of about 25,222 (249)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

A comparative study evaluating the efficacy of naltrexone versus acamprosate as anticraving agents in alcohol use disorder

Industrial Psychiatry Journal
Background: Alcohol use disorders (AUDs) are characterized by excessive alcohol consumption, negatively impacting health, social life, and economic status. Globally, AUD contributes to significant disease burden, causing millions deaths annually. Despite
Samant Singh, Lakhan Kataria, Mohd Rashid Alam   +2 more
doaj   +1 more source

Naltrexone maintenance treatment

, 2009
Naltrexone was first registered in the US in 19841 and today is available in many countries as a treatment for both heroin and alcohol dependence. This chapter reviews the safety, efficacy, and effectiveness of naltrexone as a maintenance treatment for ...
Ritter, Alison, Gibson, Amy (R17420)
core  

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers

Communications Medicine
Background The relative efficacies of nalmefene versus naltrexone for alcohol use disorder is the subject of intense and ongoing debate. The two pan-opioid receptor ligands differ primarily in actions at the kappa opioid receptor, where naltrexone acts ...
Zahra Z. Farahbakhsh, Alex R. Brown, Suzanne O. Nolan, Snigdha Mukerjee, Cody A. Siciliano   +4 more
doaj   +1 more source

Do opioid receptors play a role in the pathogenesis of the inflammatory response in acute pancreatitis? Os receptores opioides desempenham papel na patogênese da resposta inflamatória na pancreatite aguda?

Acta Cirúrgica Brasileira, 2012
PURPOSE: To investigate the effect of the opioid blocker naltrexone in the inflammatory response in acute pancreatitis (AP). METHODS: Acute pancreatitis was induced in anesthetized male Wistar rats by retrograde injection of 2.5% sodium taurocholate ...
Artur Penido, Ana Maria Mendonça Coelho, Nilza Trindade Molan, Fabiano Pinheiro da Silva, Luiz Augusto Carneiro D'Albuquerque, Marcel Cerqueira Cesar Machado   +5 more
doaj   +1 more source

Patient and Provider Demand for and Readiness to Adopt Medications for Stimulant Use Disorders in Real-World Settings: Pre-Planning Toward Accelerated Implementation. [PDF]

Drug Alcohol Rev
ABSTRACT Introduction In the United States, rates of stimulant use disorder (StUD) have increased over the last 20 years, yet fewer than one‐third of adults receive treatment. Recent research has shown the efficacy of medication for StUD, but little is known regarding demand and readiness to adopt such treatments.
Vroom EB, Finley EP, Bolton CD, Karns-Wright T, Potter JS.   +4 more
europepmc   +2 more sources

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton, Elham Kamran, Lehana Thabane, Peter Yin, Rebecca Christensen   +4 more
wiley   +1 more source